The House of Lords Science and Technology Committee will continue
taking evidence for its inquiry into Life Sciences and the
Industrial Strategy on Tuesday 7 November. The Committee will
question representatives from NHS England, Innovate UK and
Catapults.
Sir ’s life science strategy sets
out the important role the NHS must play in the UK life sciences
sector, including faster adoption of innovative new technologies
and treatments. However, there are concerns that the NHS is not
ready for this level of innovation with issues including funding,
resources and the culture of the NHS.
The Committee will explore with the witnesses their
views on how NHS England can help successfully implement the
objectives of the strategy.
The first evidence session will begin at 10.10 am and
the Committee will question:
-
Dr Ruth
McKernan, Chief Executive,
Innovate UK
-
Chris
Molloy, CEO, Medicines
Discovery Catapult
-
Keith
Thompson, CEO, Cell and Gene
Therapy Catapult
-
Professor Graham
Hillier, Strategy and
Futures Director, Centre for Process Innovation, High Value
Manufacturing Catapult
The second evidence session will begin at 11.10
am:
-
Ian
Dodge, National
Director for Strategy and Innovation
-
Professor
Mike Hannay, Director
of the East Midlands Academic Health Science
Network
-
Professor Keith
McNeil, Chief Clinical
Information Officer Health and Social Care
Topics likely to be covered across the
sessions include:
-
The role of the witnesses’ organisations in the
implementation of the strategy
-
How academics and NHS clinicians can better
collaborate on important research
-
The role of commissioners in adoption of
innovations and whether NHS Trusts should be offered financial
incentives for the adoption of innovations
-
How the relationship between UKRI and Innovate UK
will help with innovation and commercialisation of
science
The evidence session will begin at 10.10 am
on Tuesday 7 November in Committee Room 4A of the House of
Lords.
